PRESS RELEASE

PRESS RELEASE

View printer-friendly version << Back

Novavax to Host Conference Call to Discuss Third Quarter 2017 Financial Results on November 7, 2017

GAITHERSBURG, Md., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its third quarter financial and operating results following the close of U.S. financial markets on Tuesday, November 7, 2017.

Conference call details are as follows:

Date: Tuesday, November 7, 2017
Time: 4:30 p.m. U.S. Eastern Time (ET)
Dial-in number: (877) 212-6076 (Domestic) or (707) 287-9331 (International)
Passcode: 2479419
Webcast: www.novavax.com, “Investors”/ “Events”


Conference call and webcast replay:

Dates: Starts at 7:30 p.m. ET, Nov. 7, 2017 until 7:30 p.m. ET, Nov. 14, 2017
Dial-in number: (855) 859-2056 (Domestic) or (404) 537-3406 (International)
Passcode: 2479419
Webcast: www.novavax.com, “Investors”/ “Events”, until February 7, 2018


About Novavax 

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.

Contact:         

Investor Relations
Novavax, Inc.
Andrea N. Flynn, Ph.D.
Director, Investor & Media Relations
ir@novavax.com
240-268-2000
              
Westwicke Partners
John Woolford
john.woolford@westwicke.com
443-213-0506

Media
Russo Partners, LLC
David Schull
Maggie Beller
david.schull@russopartnersllc.com
maggie.beller@russopartnersllc.com
212-845-4271

 

Source: Novavax, Inc.

This site uses cookies and similar technologies to provide you with our services, enhance the performance and functionality of our services, and analyze the use of our products and services. By clicking ‘Accept’ you are indicating your consent for us to place these cookies. For more information, please read our Privacy Policy or manage your cookie settings.

Accept